Riskpilot← Back to searchSign inGet full accessValcon Medical A/S
A/SActiveCVR 40086714Industrivej 12Manufacture of other organic basic chemicals · NACE 2014Est. 201814 employees
Revenue 2024
DKK -28,2M
+87% vs 2023
EBITDA margin
122.6%
-59% vs 2023
Equity ratio
4.5%
Financial strength
Net profit 2024
DKK -41,7M
-38% vs 2023
| Revenue | DKK -28,2M | +87% |
| EBITDA | DKK -34,6M | -59% |
| Net profit | DKK -41,7M | -38% |
| Total assets | DKK 26,9M | -46% |
| Equity | DKK 1,2M | -97% |
| Employees | 14 | — |
Legal name
Valcon Medical A/S
CVR number
40086714
Legal form
Aktieselskab
NACE code
2014 · Manufacture of other organic basic chemicals
Founded
13. december 2018
Share capital
DKK 15.559.638
Employees
14 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 1 direktør sammen med bestyrelsesformanden eller af 3 bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at forestå kontraktbaseret forarbejdning og produktion af private label produkter relateret til botanisk biomasse og industriel hamp med henblik på udvinding højkvalitets ekstrakter og olier samt dermed beslægtet virksomhed.
Address
Industrivej 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -1.133 | -6.235 | -15.350 | -15.119 | -28.232 |
| Staff expenses | -2.695 | -3.067 | -9.283 | -7.887 | -10.940 |
| EBITDA | -3.828 | -9.303 | -11.347 | -21.773 | -34.600 |
| Depreciation & amort. | -0 | -3.584 | -0 | -0 | -0 |
| EBIT | -3.828 | -12.887 | -11.347 | -21.773 | -34.600 |
| Net financials | -687 | -1.435 | -568 | -2.604 | -5.387 |
| Profit before tax | -4.515 | -14.322 | -11.914 | -24.376 | -39.987 |
| Tax | -997 | -3.695 | 5.165 | 5.885 | 1.741 |
| Net profit | -3.518 | -10.627 | -17.079 | -30.262 | -41.728 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 32.540 | 57.153 | 67.255 | 50.294 | 26.909 |
| Equity | 640 | 49.435 | 56.675 | 38.684 | 1.211 |
| Long-term debt | 25.084 | 1.801 | 6.393 | 5.905 | 10.393 |
| Short-term debt | 6.816 | 5.916 | 4.186 | 5.705 | 15.305 |
| Total debt | 31.900 | 7.717 | 10.579 | 11.610 | 25.698 |
EBITDA margin
-3460040100.0%
This company
15.8%
Market median
-21898988075% vs market
20202024
Equity ratio
4.5%
This company
38.2%
Market median
-88% vs market
20202024
Return on equity
-3446.3%
This company
18.4%
Market median
-18830% vs market
20202024
Net profit margin
-4172833100.0%
This company
8.1%
Market median
-51516458125% vs market
20202024
Asset turnover
-1.05×
This company
1.12×
Market median
-194% vs market
20202024
Debt / equity
21.22×
This company
0.62×
Market median
-3323% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PE Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
PP Chief Executive Officer | Chief Executive Officer | 2021 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Former (5) | ||
| Board of Directors | 2018 – 2020 | |
| Board of Directors | 2021 – 2023 | |
| Chairman | 2018 – 2019 | |
| Board of Directors | 2019 – 2025 | |
| Board of Directors | 2023 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2025 | |
| Individual | 5–9.99% | 5–9.99% | 2025 | |
| Individual | 5–9.99% | 5–9.99% | 2025 | |
| Individual | 10–14.99% | 10–14.99% | 2023 | |
| Individual | 15–19.99% | 15–19.99% | 2024 | |
| Company | 5–9.99% | 5–9.99% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Valcon Medical A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pete Patterson | Chief Executive Officer | 0 companies |
| Peter Emil Guldmann Sigetty | Chief Executive Officer | 0 companies |
| Farzad Jahanshahi | Board of Directors | 0 companies |
| William Muecke | Board of Directors | 0 companies |
| Joel David Sherlock | Board of Directors | 0 companies |
| Alex Sung Kwon | Chairman | 0 companies |
| Diego Francisco Gomez Dueñas | Board of Directors | 0 companies |
| Pete Patterson | Board of Directors | 0 companies |
| Ruchir Ashok Kadakia | Board of Directors | 0 companies |
| Mike Steen Hansen | Chairman | 0 companies |
| NELSON CAMARGO CURY | Board of Directors | 0 companies |
| E Stanton Mclean | Board of Directors | 0 companies |